Article: Wyeth Renews Subscription to Gene Logic's BioExpress System.

Business Editors/Health/Medical Writers

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 28, 2003

Gene Logic Inc. (Nasdaq:GLGC) today announced that the global pharmaceutical company Wyeth (NYSE: WYE) has renewed its subscription agreement for access to Gene Logic's BioExpress(TM) System.

Financial details of the multiyear renewal agreement were not disclosed.

Commenting on the renewal agreement, Mark D. Gessler, Chairman and CEO of Gene Logic, said, "Wyeth has an extensive drug discovery and development program. The renewal demonstrates that Wyeth continues to focus on what matters most to their business success--identifying promising lead ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!